Aesica estimates that the facility, housed in a purpose-built facility at its Queenborough, Kent site, will be completed by May 2011 and once operational will manufacture potent drugs typically classed as Safebridge category 3. The facility will also include security measures to enable it to produce Schedule II controlled drugs such as opiates.
Suites for granulation, tabletting and blister packing, plus appropriate HVAC and cleaning facilities will be built in the high containment unit. It will be separate from the rest of the company’s facilities to prevent cross-contamination.
Adam Sims, Aesica’s commercial director, said: ‘Our service offering and capability is the most advanced in the UK and the addition of the new facility will be of huge benefit to our current clients and indeed all pharmaceutical companies who require potent drug product production.’
Aesica supplies contract development and contract manufacturing services for active pharmaceutical ingredients and formulated products to the world’s leading pharmaceutical companies and emerging biotechnology organisations.
You may also like
Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles
You may also like
How contract manufacturers can bridge the innovation–commercialisation divide
With R&D budgets under pressure, the pharmaceutical industry would do well to look to the contract manufacturing sector for innovative approaches and technologies that could make production more effective and efficient, and achieve more with finite resources